US 11,654,121 B1
Combination therapies for the treatment of viral infections
David Barry Kolesky, Arlington, MA (US); Michael Ka Chun Wong, Arlington, MA (US); and Hok Hei Tam, Newton, MA (US)
Assigned to Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed by Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed on Aug. 1, 2022, as Appl. No. 17/878,469.
Claims priority of provisional application 63/394,030, filed on Aug. 1, 2022.
Claims priority of provisional application 63/354,490, filed on Jun. 22, 2022.
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/122 (2006.01); A61P 31/14 (2006.01); A61K 31/706 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 31/706 (2013.01); A61P 31/14 (2018.01)] 18 Claims
 
1. A method of treating a SARS CoV-2 infection in a human subject, comprising administering a combination of (i) hypericin or a pharmaceutically acceptable salt thereof and (ii) remdesivir or a pharmaceutically acceptable salt thereof to the human subject,
wherein the molar amount of the hypericin or a pharmaceutically acceptable salt thereof in the combination is greater than the molar amount of remdesivir or a pharmaceutically acceptable salt thereof,
thereby treating the SARS CoV-2 infection in the human subject.